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ABSTRACT 26 
Objective 27 
Respiratory disease is a major cause of morbidity and mortality in HIV-infected children. Despite 28 
antiretroviral therapy (ART), children suffer chronic symptoms. We investigated symptom 29 
prevalence, lung function, and exercise capacity among older children established on ART, and an 30 
age-matched HIV-uninfected group. 31 
Design 32 
A cross-sectional study in Zimbabwe of: 1) HIV-infected children aged 6-16 years receiving ART 33 
for over six months; 2) HIV-uninfected children attending primary health clinics from the same 34 
area.  35 
Methods 36 
Standardised questionnaire, spirometry, Incremental Shuttle Walk Testing (ISWT), CD4 count, 37 
HIV viral load, and sputum culture for tuberculosis were performed. 38 
Results 39 
202 HIV-infected and 150 uninfected participants (median age 11.1 years in each group) were 40 
recruited. Median age at HIV diagnosis and ART initiation was 5.5 (IQR 2.8-7.5) and 6.1 years 41 
(IQR 3.6-8.4) respectively. Median CD4 count was 726 cells/µl, and 79% had HIV viral 42 
load<400copies/ml. Chronic respiratory symptoms were rare in HIV-uninfected children (n=1 43 
[0.7%]), but common in HIV-infected participants (51 [25%]), especially cough (30 [15%]) and 44 
dyspnoea (30 [15%]). HIV-infected participants were more commonly previously treated for 45 
tuberculosis (76 [38%] versus 1 [0.7%], p<0.001), had lower exercise capacity (mean ISWT 46 
distance 771m versus 889m respectively, p<0.001), and more frequently abnormal spirometry (43 47 
[24.3%] versus 15 [11.5%], p=0.003) compared to HIV-uninfected participants. HIV diagnosis at 48 
  
an older age was associated with lung function abnormality (p=0.025). No participant tested 49 
positive for M. tuberculosis. 50 
Conclusions 51 
In children, despite ART, HIV is associated with significant respiratory symptoms and functional 52 
impairment. Understanding pathogenesis is key, as new treatment strategies are urgently required. 53 
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INTRODUCTION 57 
Respiratory disease is the most common manifestation of HIV/AIDS among children, accounting 58 
for more than 50% of HIV-associated mortality.[1-4] The use of antiretroviral therapy (ART) and 59 
co-trimoxazole prophylaxis has contributed to a reduction in the rate of acute respiratory tract 60 
infections and mortality among HIV-infected children in both high- and low-resource settings.[5] In 61 
the pre-ART era, 30-40% of HIV-infected children also developed chronic lung disease, most 62 
commonly due to lymphoid interstitial pneumonitis (LIP), but this condition responds well to ART 63 
and is now uncommon in clinical practice, except in children under 5 years old.[6-8]   64 
Nevertheless, recent studies in southern Africa have demonstrated that about 30% of African HIV-65 
infected older children have chronic respiratory symptoms, classically a chronic cough (often 66 
leading to presumptive treatment for tuberculosis (TB)) and reduced exercise tolerance.[3, 4] In 67 
these studies, even participants with pronounced respiratory impairment looked well at rest, not all 68 
had cough, and plain radiological abnormalities were subtle, and not consistent with LIP.[9] 69 
However, these studies did not include HIV-uninfected controls, and included a mix of children 70 
who were ART naïve as well as those taking ART. The aim of this study was to investigate the 71 
burden and features of chronic lung disease among HIV-infected children established on ART and 72 
in an age-matched HIV-uninfected group.  73 
 METHODS 74 
The study was carried out between September 2014 and June 2015 at the Harare Children’s 75 
Hospital HIV clinic in Harare, Zimbabwe, a public sector clinic that provides HIV care for more 76 
than 4000 children. Children were eligible for the study if they were aged between 6 and 16 years, 77 
had been taking ART for at least 6 months, were not acutely unwell and were not taking TB 78 
treatment. We consecutively recruited up to five eligible participants per day, restricted to this 79 
number due to logistical constraints. A comparison group of HIV-uninfected children in the same 80 
  
age group was also recruited from 7 clinics which provided HIV testing and counselling to all 81 
attendees regardless of the reason for attendance, and which served the same population as that of 82 
Harare Hospital (high population density suburbs, with small dwellings being typical). We enrolled 83 
children who had tested HIV-negative and who were not acutely unwell and who were not receiving 84 
treatment for respiratory infection or tuberculosis. A sample size of 200 HIV-1 infected children 85 
was selected to provide a precision of ±6% around an estimated 25% prevalence of chronic lung 86 
disease (CLD), defined as any one of: unexplained chronic cough for ≥3 months; hypoxaemia 87 
(SpO2 <90%) at rest or desaturation on exertion by more than 4% from baseline; abnormal 88 
spirometry without another medical explanation e.g. asthma; chronic dyspnoea (MRC 89 
breathlessness score >1)[10]. 90 
Data collection 91 
A nurse-administered questionnaire was used to collect details of socio-demographic indices, 92 
clinical history and current symptoms. A standardised examination was performed including WHO 93 
staging of HIV infection, measurement of height and weight, spirometry and exercise testing. 94 
Spirometry was performed according to ATS standards using EasyOne World spirometers (ndd 95 
Medical Technologies, Inc., Andover, MA, USA).[11] Up to 8 forced exhalations were recorded 96 
while sitting. We analysed only data from individuals who produced three consistent traces which 97 
met ATS quality criteria. The highest FEV1 and FVC measurements for each individual were used, 98 
with other indices recorded from the best trace (largest total of FEV1 and FVC). Obstruction was 99 
defined as a reduced FEV1:FVC. For clarity, we use the term "reduced FVC" where FVC was low 100 
with a normal FEV1:FVC. We avoided the term "restriction" as we were unable to measure lung 101 
volumes. Where any spirometric abnormality was found, participants underwent repeat spirometry 102 
15 minutes after administration of 2.5mg nebulised salbutamol. An improvement inFEV1 of ≥12% 103 
was considered to represent significant reversibility. 104 
  
An incremental shuttle walk test was performed as a measure of cardiorespiratory fitness. This was 105 
devised for adults,[12] but has been validated for use in children with chronic respiratory 106 
disease.[13] Participants were not tested if, at rest: SpO2 <88%; heart rate >110; respiratory rate 107 
>30 breaths/min. On flat ground, participants were instructed to walk between two markers placed 108 
10 metres apart. A pre-recorded series of "bleeps" were played, which determined how quickly each 109 
10 metre segment should be completed. The standardised protocol demanded that the participant 110 
walked 30 metres in the first minute, with each subsequent minute escalating the distance by 10 111 
metres (i.e. 40, 50 and 60 metres in the 2nd, 3rd and 4th minutes respectively). The test was 112 
terminated when participants were unable to reach the next marker by the time the beep was issued. 113 
The respiratory rate, heart rate and oxygen saturations were measured before and immediately after 114 
the end of the test. Only the first 82 participants in the HIV-uninfected group underwent SWT due 115 
to limited staffing. Predicted maximal heart rates were calculated by the Tanaka equation: 208 - 116 
0.7*age.[14] 117 
Laboratory investigations 118 
Where possible, all HIV positive participants had sputum samples obtained by spontaneous 119 
expectoration or by induction using nebulised hypertonic saline. Sputum smears were examined by 120 
Ziehl-Neelson stain microscopy and a single mycobacterial culture was performed on Lowenstein-121 
Jensen media. Sputum from HIV uninfected participants was sought only if the WHO TB symptom 122 
screen was positive.[15] HIV viral load was measured with COBAS Ampliprep/Taqman 48 Version 123 
2.0 and CD4 count was measured using an Alere PIMA™ CD4 machine (HIV-positive participants 124 
only). 125 
Data Analysis 126 
Data were extracted from paper forms using optical character recognition software (Cardiff 127 
TELEFORM Intelligent Character, Version 10.7). Data analysis was carried out using Stata v12 128 
  
(StatCorp, TX) and GraphPad Prism v6 (GraphPad, CA). Height-for-age and BMI-for-age z-scores 129 
were calculated using the WHO reference standards.[16] Normal spirometric ranges were defined 130 
using the GLI 2012 equation which determines race and sex specific reference values, taking 131 
account of height and age.[17] The lower limit of normal (LLN) is defined as 1.64 standard 132 
deviations below the mean expected value (which describes the lowest 10 centiles as "abnormal"). 133 
Shuttle walk and CD4 results were treated as parametric data, with Student t test used to compare 134 
means between HIV-infected and non-infected groups. Other continuous variables were non-135 
parametric: central tendency was reported by the median and interquartile range (IQR), using the 136 
Mann-Whitney U test for equivalence testing between groups. Frequencies of categorical data - 137 
symptoms, past medical complaints and rates of abnormal spirometry and growth indices - were 138 
compared between HIV-infected and non-infected by chi squared test. Results were considered 139 
statistically significant at p<0.05. The association of abnormal lung function with a priori defined 140 
clinical data were investigated using univariable logistic regression, and reporting Odds ratios with 141 
a Wald 95% confidence interval. Stepwise backward multivariate logistic regression was then used; 142 
this incorporated age and sex, and those variables with individual p<0.1 on univariate testing. 143 
Ethical approval was granted by the Medical Research Council of Zimbabwe, the Harare Hospital 144 
Ethics Committee, the Biomedical Research and Training Institute Institutional Review Board and 145 
the London School of Hygiene and Tropical Medicine Ethics Committee. All guardians gave 146 
written consent and participants gave assent to participate.in the study. 147 
RESULTS 148 
Participant characteristics 149 
A total of 202 HIV-infected participants were recruited: median age 11.1 years (IQR 9.0 – 12.9), 150 
and 55% male. Summary statistics are given in Table 1, and a flow diagram of participation and 151 
testing is given in Figure 1. Of the 150 HIV-uninfected participants recruited as a comparison 152 
group, 42% were male and the median age was 11.0 (IQR 9.0-13.9).  All but one HIV-infected 153 
participants were vertically-infected and the median age at HIV diagnosis was 5.5 (IQR 2.8 – 7.5) 154 
  
years. The median duration of ART was 4.7 (IQR 2.6 – 6.4) years, with 161 (80%) taking non-155 
nucleoside reverse transcriptase inhibitor-based (first-line) ART and the remainder taking a protease 156 
inhibitor based regimen (  157 
  
Table 3). The median CD4 count at HIV diagnosis (available for 105 participants) was 353 (IQR 158 
134 – 696) cells/µl and the CD4 count at enrolment was 726 (IQR 476 – 941) cells/µl. The majority 159 
of participants (79%) had an HIV viral load <400copies/ml (Table 1), and 194 (96%) were taking 160 
co-trimoxazole. 161 
None of the HIV-uninfected participants screened positive using the WHO TB symptom screen. 162 
Within the HIV infected group, 153 participants produced samples for mycobacterial culture, 35 163 
could not despite sputum induction, and 16 were too ill or did not return for the procedure.  None 164 
grew Mycobacterium tuberculosis, but 3 grew non-tuberculous mycobacteria (not speciated).  165 
A significantly higher proportion of HIV-infected participants were stunted than HIV-uninfected 166 
participants (35.8% vs. 7.3%, p<0.001), but prevalence of wasting was similar in the two groups 167 
(Table 1). Seventy-six HIV-infected children had been previously treated for tuberculosis, 168 
compared with one from the HIV-uninfected group.  169 
The proportion treated for asthma was similar in both groups. Chronic respiratory symptoms 170 
(breathlessness, cough or wheeze) were reported by 25.3% of HIV-infected children but only by 171 
one (0.7%) HIV-uninfected child. Wheeze was infrequently reported in either group (Table 1).  172 
Incremental Shuttle Walk Test (ISWT) could not be performed in 15 HIV infected participants due 173 
to resting hypoxaemia (n=2), resting dyspnoea (n=9), or loss to follow-up (n=4). One HIV-174 
uninfected participant had tachypnoea at rest. The distance attained during ISWT was significantly 175 
reduced in the HIV-infected group (mean 771m [SD 216] compared with 889m [SD 227] in the 176 
HIV-uninfected group, p<0.001). Shortly after completion of the test, mean heart rate was not 177 
significantly difference at 62% (SD 12.0) and 67% (SD 10.5) of their predicted maximal heart rates 178 
for the HIV infected and non-infected groups respectively.  179 
  
One hundred and seventy-seven (88%) HIV-infected and 130 (87%) HIV-uninfected participants 180 
had high-quality spirometry traces. Quality grading according to ATS standards did not differ 181 
between groups either before or after reversibility testing. Of those high quality (interpretable) 182 
traces, a quarter of all HIV-infected participants had abnormal lung function on spirometry. This 183 
was significant higher than among HIV-uninfected participants (24.3% vs 11.5%, p=0.01). This 184 
was reflected in lower FEV1, FVC and FEF25-75 indices in the HIV-infected group (p<0.05) 185 
(Figure 2). There was no significant difference in the FEV1:FVC ratio (p=0.08) between the two 186 
groups, although those with a history of lung infection had a lower FEV1:FVC than those without 187 
(p=0.03). For those with spirometric abnormality, post bronchodilator reversibility traces were 188 
complete and adequate in 31 HIV-infected and 6 HIV-uninfected participants, demonstrating 189 
reversibility in 11 (35.4%) and 2 (33.33%) respectively. 190 
Predictors of abnormal lung function are summarised in Table 4. When subdivided into restrictive 191 
and obstructive types, numerators were insufficient to draw robust conclusions: data are therefore 192 
presented as “normal” or “abnormal”. The presence of any respiratory symptom, except wheeze, 193 
was significantly associated with abnormal lung function. Older age at HIV diagnosis was 194 
positively associated with abnormal lung function (p=0.025), as was wasting (OR 8.1, 95% CI 2.3-195 
31.7). After fitting a multivariate model, wasting was the only independent predictor: OR 4.7 (95% 196 
CI 1.2 – 18.6). 197 
We investigated the potential for prior respiratory infection to impact on lung function by stratified 198 
analysis (Figure 2 and Supplemental Table S1). Among those with previous infection (any of: TB; 199 
PCP; NTM by sputum culture; hospitalisation for chest infection), those with later presentation and 200 
ART initiation were more likely to have abnormal lung function (p<0.05). Dyspnoea, tachypnoea, 201 
oxygen desaturation and wasting were also disproportionately apparent (p<0.05 for each). However, 202 
  
among those without previous infection, cough and sputum production were more commonly seen 203 
in those with abnormal spirometry (p<0.05) 204 
DISCUSSION 205 
A quarter of HIV infected children experienced chronic respiratory symptoms, despite being treated 206 
with ART and with good virological control in the majority. In contrast, only one HIV-uninfected 207 
participant reported respiratory symptoms. More than one third of the HIV-infected children in our 208 
study had been previously treated for TB, although we were unable to determine how the diagnosis 209 
of TB had been made due to a lack of robust records. As noted in other cohorts, where background 210 
TB rates are high, over-treatment is likely in those with chronic respiratory symptoms due to a lack 211 
of diagnostic and alternative therapeutic strategies for chronic respiratory symptoms.[18, 19] 212 
Notably, no TB was found in our study on microbiological investigation.  213 
We found much higher rates of abnormal lung function among HIV-infected compared to HIV-214 
uninfected children. Development of airways disease in early life has been described in the context 215 
of HIV infection: airway resistance measurements indicate that abnormalities of airway calibre are 216 
established in those as young as one year old.[20] However, in resource limited settings, no 217 
longitudinal studies have been conducted to define how such abnormalities change over time, or 218 
how they respond to ART. Interestingly, in our current study, obstructive lung disease was less 219 
common than in a study conducted in Malawi (4% vs 26%).[21] In the Malawi study, however, 220 
31% of individuals were ART-naïve or had been taking ART for a relatively shorter duration 221 
(median 20 months).[2]  222 
In the pre-ART era, the most common cause of CLD was lymphocytic interstitial pneumonitis (LIP) 223 
found in 30-40% of HIV-infected children.[7, 22] LIP responds well to ART and the prevalence has 224 
significantly declined with increased availability of ART.[23] We found low rates of wheeze and 225 
bronchodilator response which would suggest that the chronic respiratory symptoms are not likely 226 
  
to be due to asthma. Similarly, although household air pollution is detrimental to lung function and 227 
can cause these symptoms, rates of biomass as the main fuel for cooking or lighting are lower in our 228 
cohort (less than 1 in 5) than other reported peri-urban series in sub-Saharan Africa, due to access to 229 
mains electricity.[24] 230 
In the ART era, multiple aetiological factors may contribute to lung disease, including long-term 231 
sequelae of repeated bacterial and viral respiratory tract infections and possibly HIV-induced 232 
chronic inflammation and immune senescence caused by dysregulated immune activation.[25, 26]  233 
Such processes account for the high prevalence of bronchiectasis in this population, and may also 234 
contribute to obliterative bronchiolitis (OB).[18, 22] The latter has been described in a previous 235 
study from Zimbabwe. It seems to represent, as in non-HIV related OB, a final common pathway of 236 
lung injury typified radiologically by air trapping and mosaic attenuation of the lung 237 
parenchyma.[2, 9] The features on plain chest radiography are subtle and non-specific, and high 238 
resolution CT is the definitive imaging modality. The lack of HRCT facilities may explain why OB 239 
is not recognised in Africa, despite the high prevalence of chronic respiratory symptoms.[27-30] 240 
Clinically, OB usually presents as an obstructive lung disease with minimal response to inhaled beta 241 
agonists. However, the pattern of spirometry abnormalities observed in our study was mainly 242 
restrictive. This might be explained by chronic immune activation causing scarring and fibrosis, 243 
resulting in a restrictive lung function abnormality.[31-33] We found a reduced FEV1/FVC ratio - a 244 
more obstructive pattern - in those with a previous history of infection. This would be consistent 245 
with unrecognised OB which has been treated as TB or other infection. However, TB in adults is 246 
itself known to leave evidence of airway obstruction, even in those cured of disease. 247 
. our finding that later diagnosis is associated with abnormal spirometry suggests that early 248 
diagnosis and treatment of HIV may prevent development or progression of chronic lung disease. 249 
Established disease appears to persist despite otherwise effective ART. This was apparent children 250 
  
with a history of infection, where later initiation of ART, and signs of reduced gas-exchange 251 
capacity (oxygen desaturation and tachypnoea) predicted lung function abnormality. Wasting, also a 252 
predictor of lung function abnormality, could represent by association many risk factors for lung 253 
disease, including nutrition and chronic inflammatory disease. 254 
In our cohort, there was no significant correlation between lung function abnormality and SWT 255 
distance. The Incremental Shuttle Walk Test (ISWT) is a valid and reproducible predictor of 256 
aerobic exercise capacity (VO2 peak). As a maximal test, it is less variable than self-paced protocols 257 
such as the six-minute walk test.[13] VO2 peak is determined by both respiratory and cardiovascular 258 
fitness. It is possible that the reduced exercise capacity in HIV infected children might be partly due 259 
to cardiac disease. Previously noted echocardiographic abnormalities in Zimbabwean children 260 
include LV hypertrophy and diastolic dysfunction, seen in 74/110 (67%) and 27/110 (24%) 261 
respectively.[34] We are further investigating this possibility using echocardiography in our cohort. 262 
The strengths of this study was that it was prospectively conducted, recruitment was unselective 263 
(i.e. not based on presence of respiratory symptoms) and from a general HIV clinic. It included an 264 
HIV-uninfected comparison group recruited from the same geographical area. Study limitations 265 
include self-report of illness which may result in recall bias. Spirometry was not available for all 266 
participants due to exclusion of poor quality traces and ISWT was not universally performed in 267 
HIV-uninfected participants due to staff shortages. Furthermore, we were unable to measure lung 268 
volumes. Our HIV-uninfected group were not matched by sex, resulting in females being slightly 269 
more frequently represented compared to in the HIV-infected group. However, this should not 270 
affect interpretation for spirometry data as lung function indices use sex-specific normal ranges. For 271 
exercise capacity, male children tend to outperform females, but sub-analysis of our data stratified 272 
by sex revealed no difference in findings (data not shown).[35]  273 
  
Our study demonstrates that there is a large burden of chronic respiratory morbidity among HIV-274 
infected children established on ART.  Despite efforts to eliminate mother to child transmission, 275 
300,000 infants were newly infected with HIV in 2011, and a record number (630,000) were 276 
receiving ART in low income countries.[36, 37] Thus, HIV will continue to place a heavy burden 277 
on paediatric clinical services in sub-Saharan Africa, where 90% of the world’s HIV-infected 278 
children live.[38] Delay in diagnosis of HIV infection and initiation of ART may increase the risk 279 
of developing chronic lung disease. The WHO until 2015 had recommended that children aged over 280 
five years should be treated with ART once CD4 count drops to 500cells/µl or Stage 3 or 4 disease. 281 
The recent START and TEMPRANO trials in adults demonstrated that treating HIV infection 282 
irrespective of immunological status reduces the risk of AIDS and non-AIDS events.[39, 40] In 283 
children, earlier HIV recognition, may reduce the risk of developing chronic lung disease by 284 
preventing recurrent respiratory tract infection and by reducing chronic pulmonary inflammation. 285 
Adoption of universal treatment of all HIV-infected individuals regardless of disease stage  may 286 
therefore be advantageous, and some additional benefit might be expected from co-trimoxazole 287 
prophylaxis by lowering the rates of lower respiratory tract infection. However, once established, 288 
chronic lung disease appears to persist despite ART. Hitherto the main focus of HIV programs has 289 
been on meeting the need for massive scale-up of paediatric antiretroviral therapy (ART) and on 290 
improving infant survival.  There is now a pressing need to address the long term complications of 291 
HIV infection among the increasing numbers of children growing up with HIV, and novel 292 
diagnostic and therapeutic strategies for chronic lung disease are urgently required.  293 
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Table 1: Summary characteristics of study participants by HIV status 412 
 HIV uninfected 
(n=150) 
HIV infected 
(n=202) 
p-value 
Age, median years (IQR) 11.1 (9.0 – 12.8) 11.1 (9.0 – 12.9) 0.77 
Sex, female, n (%) 63 (42.0) 111 (55.0) 0.018 
Orphan, n (%) 20 (13.5) 102 (51.0) < 0.001 
Mother known to be HIV infected 13 (8.7) 202 (100) < 0.001 
Active smoker, n (%) 0 (0) 0 (0) - 
Passive smoke exposure at home, n (%) 27 (18.0) 42 (20.9) 0.18 
Any respiratory complaint*, n (%) 1 (0.7) 51 (25.3) < 0.001 
Dyspnoea (MRC grade>1), n (%) 0 (0) 30 (14.9) < 0.001 
Daily cough for >1 month, n (%) 1 (0.7) 30 (14.9) < 0.001 
Sputum production, n (%) 1 (0.7) 20 (10.0) < 0.001 
Wheeze, n (%) 0 (0) 9 (4.5) 0.007 
Resting tachypnoea: rate >25, n (%) 9 (6.0) 28 (14.1) 0.016 
Hospital admission for RTI in last year, n (%) 3 (2.0) 4 (2.0) 0.96 
Antibiotics for RTI in last year, n (%) 3 (2.0) 45 (22.3) < 0.001 
Previously diagnosed or treated    
  Asthma, n (%)  3 (2.0) 7 (3.5) 0.37 
  PCP, n (%)  0 (0) 6 (3.0) 0.029 
 Tuberculosis ever, n (%)  1 (0.7) 76 (37.8) < 0.001 
 Tuberculosis more than once, n (%)  0 (0) 5 (2.5) 0.10 
Stunted (HFA z score <2), n (%) 12 (7.9) 72 (35.8) < 0.001 
Wasting (BFA z score <2), n (%) 10 (6.7) 18 (9.0) 0.42 
Incremental Shuttle Walk Test (ISWT) (n=82) (n=187)  
 Desaturates during test, n (%) 5 (6.1) 22 (11.1) 0.16 
 ISWT distance, metres mean (SD) 889 (227) 771 (216) < 0.001 
Spirometry interpretation (n=130) (n=177)  
 Normal, n (%) 115 (88.5) 134 (75.7) 0.003 
 Obstruction, n (%) 1 (0.8) 7 (4.0) 0.052 
 Reduced FVC, n (%) 14 (10.8) 36 (20.3) 0.012 
Bronchodilator response (n=6) (n=31)  
  
 Reversibility demonstrated, n (%) 2 (33.3) 11 (35.5) 0.92 
* wheeze, chronic cough or dyspnoea; IQR interquartile range; SD standard deviation; HFA height 413 
for age; BFA body mass for age; RTI respiratory tract infection; missing data on n=2. 414 
  415 
  
Table 2 HIV-specific summary characteristics 416 
 HIV infected (n=202) 
Age at diagnosis, median (IQR) 5.5 (2.8 – 7.5) 
Age at ART initiation, median (IQR) 6.1 (3.6 – 8.4) 
Mode of HIV transmission, n (%)  
 Mother to child 201 (99.5) 
 Sexual 1 (0.5) 
Reason for HIV testing  
 Chronic cough 113 (55.9) 
 Hospital admission 41 (20.3) 
 Repeated illness 32 (15.8) 
 Other ‡ 16 (7.9) 
CD4 at diagnosis, median (IQR) † 353 (134 – 696) 
CD4, median (IQR) at recruitment 726 (476 – 941) 
HIV VL <400 copies/ml, n (%) 155 (78.7) 
 417 
† Data available for 105 participants from health records; ‡ Other reasons were: testing in elective 418 
male circumcision (n=6); spontaneous healthcare worker initiated (n=2); TB diagnosed (n=1); 419 
sexual debut prompted testing (n=1); don’t recall (n=6). 420 
  421 
  
Table 3 HIV treatment regimes 422 
 NNRTI based PI based 
 NVP EFV ATAZ/r LPV/r 
AZT/3TC* 72 23 7 2 
TDF/3TC 32 32 25 - 
ABC/3TC - 1 2 - 
ABC/DDI - 1 2 1 
Total † 161 39 
AZT = zidovudine; 3TC = stavudine; TDF = tenofovir; ABC = abacavir; DDI = didanosine; NVP = 423 
nevirapine; EFV = efavirenz; ATAZ/r = ritonavir boosted atazanavir; LPV/r = ritonavir boosted 424 
lopinavir. 425 
*1 individual unknown NNRTI or PI. 1 individual DDI/ATAZ/r with 2nd NRTI unrecorded  426 
  
Table 4: Association of factors with abnormal lung function in HIV-infected children 427 
 Normal 
n=134 
Abnormal 
n=43 
OR (95% CI) 
Age at diagnosis†, n (IQR) 4.6 (2.7 – 6.7) 5.8 (3.8 – 8.8) 1.15 (1.02 – 1.29)* 
Age at ART initiation†, n (IQR) 5.8 (3.5 – 8.3) 6.3 (4.3 – 8.8) 1.05 (0.95 – 1.17) 
Years on ART, n (IQR) 4.6 (2.3 – 6.4) 5.1 (3.4 – 6.4) 1.08 (0.95 – 1.23) 
Any symptom, n (%) 25 (18.7) 20 (46.5) 3.8 (1.7 – 8.5)* 
Dyspnoea, n (%) 13 (9.7) 14 (32.6) 4.5 (1.7 – 11.5)* 
Daily cough, n (%) 12 (9.0) 13 (30.2) 4.4 (1.7 – 11.7)* 
Sputum production, n (%) 7 (5.2) 9 (20.9) 4.8 (1.5 – 16.2)* 
Wheeze, n (%) 6 (4.5) 3 (7.0) 1.6 (0.2 – 7.9) 
Passive smoker 33 (24.6) 9 (20.9) 0.8 (0.3 – 2.0) 
Biomass fuel used for cooking 21 (15.7) 8 (18.6) 1.2 (0.4 – 3.2) 
Biomass fuel or candles used for lighting 18 (13.4) 6 (14.0) 1.0 (0.3 – 3.0) 
Previous TB treatment, n (%) 49 (36.6) 18 (41.9) 1.2 (0.6 – 2.7) 
Stunting (HFA<-2), n (%) 45 (33.6) 19 (44.2) 1.6 (0.7 – 3.3) 
Wasting (BFA <-2), n (%) 5 (3.7) 10 (3.8) 8.1 (2.3 – 31.7)* 
Abnormal SpO2 at rest or exercise, n (%) 11 (8.5) 9 (23.1) 3.2 (1.1 – 9.4)* 
Resting tachypnoea (rate >25), n (%) 16 (12.1) 8 (19.1) 1.7 (0.6 – 4.7) 
Viral load suppressed <400 copies/mla 105 (80.2) 32 (78.1) 0.9 (0.4 – 2.4) 
ISWT distance, metres (SD) b 765 (212) 771 (241) 1.00 (1.00 – 1.00) 
CD4 at recruitmentc 774 (342) 688 (344) 1.00 (1.00 – 1.00) 
* Significant at p<0.05 428 
a n=131 and n=41 respectively; b n=131 and n=38 respectively; c n=134 and n=42 respectively  429 
  
Figure 1 Flowchart of participant recruitment and testing 430 
Diagram showing recruitment of HIV-infected participants. 431 
 432 
n=4 did not attend for follow-up appointment, and therefore did not undergo SWT 433 
NTM: non-tuberculous mycobacteria   434 
  
Figure 2 Spirometric abnormalities in HIV infected and uninfected participants 435 
Dot plots of all participants with spirometry results, presented as z-scores compared with GLI 2012 436 
reference ranges. Bars illustrate the mean and standard deviations of each group. Dotted horizontal 437 
bars show the limits of normality. P values derive from t-tests. HIV infected individuals are further 438 
shown by stratification by “Prior lung infection”. This is a compound definition, including 439 
individuals with any of: TB; PCP; NTM by sputum culture; hospitalisation for chest infection. 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
  
454 
  
Supplementary Table S1 455 
Stratified analysis of the associations of pre-selected clinical and physiological characteristics with abnormal lung function. 456 
 No prior infection (n=105) Prior infection (n=72) 
 Normal 
n=82 
Abnormal 
n=23 
OR (95% CI) Normal 
n=52 
Abnormal 
n=20 
OR (95% CI) 
Age at diagnosis†, n (IQR) 4.6 (2.2 – 6.7) 4.4 (3.7 – 7.5) 1.05 (0.90 – 1.23) 4.6 (3.3 – 6.7) 7.9 (5.0 – 9.0) 1.30 (1.07 – 1.59)* 
Age at ART initiation†, n (IQR) 6.1 (3.2 – 8.4) 5.4 (3.7 – 7.9) 0.96 (0.83 – 1.10) 5.3 (3.6 – 8.3) 8.0 (5.7 – 9.9) 1.19 (1.00 – 1.41)* 
Years on ART, n (IQR) 4.3 (2.1 – 6.4) 5.4 (3.7 – 6.7) 1.05 (1.00 – 1.42)* 4.6 (3.0 – 6.5) 4.5 (2.7 – 6.4) 0.94 (0.76 – 1.15) 
Any symptom, n (%) 14 (17) 7 (30) 2.1 (0.7 – 6.1) 11 (21) 13 (65) 6.9 (2.2 – 21.5)* 
Dyspnoea, n (%) 9 (11) 5 (22) 2.3 (0.7 – 7.5) 4 (8) 9 (45) 9.8 (2.6 – 37.8)* 
Daily cough, n (%) 4 (5) 6 (26) 6.9 (1.7 – 27.1)* 8 (15) 7 (35) 3.0 (0.9 – 9.7) 
Sputum production, n (%) 2 (2) 4 (17) 8.4 (1.4 – 49.3)* 5 (10) 5 (25) 3.1 (0.8 – 12.3) 
Wheeze, n (%) 4 (5) 1 (4) 0.9 (0.1 – 8.3) 2 (4) 2 (10) 2.8 (.04 – 21.2) 
Passive smoker, n (%) 22 (27) 6 (26) 1.0 (0.3 – 2.8) 11 (21) 3 (15) 0.7 (0.2 – 2.6) 
Biomass fuel used for cooking, n (%) 12 (15) 5 (22) 1.6 (0.5 – 5.2) 9 (17) 3 (15) 0.8 (0.2 – 3.5) 
Biomass fuel or candles used for lighting, n (%) 11 (13) 3 (13) 1.0 (0.2 – 3.9) 7 (13) 3 (15) 1.1 (0.3 – 4.9) 
Stunting (HFA<-2), n (%) 22 (27) 7 (30) 1.2 (0.4 – 3.3) 23 (44) 12 (60) 1.9 (0.7 – 5.4) 
Wasting (BFA <-2), n (%) 3 (4) 3 (13) 4.0 (0.7 – 21.2) 2 (4) 7 (37) 14.6 (2.7 – 79.3)* 
Abnormal SpO2 at rest or exercise, n (%) 7 (9) 4 (19) 2.5 (0.6 – 9.3) 4 (8) 5 (28) 4.4 (1.0 – 18.9)* 
Resting tachypnoea (rate >25), n (%) 13 (16) 3 (14) 0.8 (0.2 – 3.2) 3 (6) 5 (25) 5.3 (1.1 – 25.0)* 
  
Viral load suppressed <400 copies/mla 60 (75) 18 (86) 2.0 (0.5 – 7.5) 45 (88) 14 (70) 0.3 (0.1 – 1.1) 
ISWT distance, metres (SD)b 803 (223) 804 (254) 1.00 (1.00 – 1.00) 704 (180) 730 (223) 1.00 (1.00 – 1.00) 
CD4 at recruitmentc, cells/µl (SD) 761 (343) 658 (259) 1.00 (1.00 – 1.00) 794 (342) 721 (423) 1.00 (1.00 – 1.00) 
“Prior infection” uses a compound definition of any of the following: previous TB treatment; previous PCP treatment; admitted to hospital with 457 
infection in the preceding 12 months; mycobacteria isolated in sputum culture 458 
a: No prior infection - normal n=80, abnormal n=21; Prior infection - normal n=51, abnormal n=20 459 
b: No prior infection - normal n=80, abnormal n=21; Prior infection - normal n=51, abnormal n=17 460 
c: No prior infection - normal n=82, abnormal n=22; Prior infection - normal n=52, abnormal n=20 461 
* significant at p<0.05 462 
 463 
 464 
